This article is more than 5 years old. Information may no longer be current.

Lee’s Pharmaceutical to license RegeneRx dry eye treatment candidate in China, Taiwan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RegeneRx Biopharmaceuticals has entered into an agreement for Lee’s Pharmaceutical Limited to license RegeneRx’s thymosin beta 4-based product candidates in China and Taiwan, according to a news release.

The agreement covers three products in phase 2 clinical development, including RGN-259, a sterile, preservative-free topical eye drop that has demonstrated statistically significant improvements in signs and symptoms of moderate and severe dry eye syndrome, the release said.

The licensing agreement also covers product candidates for the treatment of cardiovascular, nervous system and skin diseases.

Lee’s has already paid RegeneRx $200,000 and will pay an additional $200,000 with the completion of this license agreement, according to the release. Potential milestone payments of up to $3.6 million and commercial sale royalties are also included in the agreement.

Any improvements Lee’s makes to RegeneRx’s products may be licensed exclusively by RegeneRx outside the territory covered in the licensing agreement, according to the release.